Axcella
Cambridge
About Axcella
Axcella is a clinical-stage biotechnology company that treats complex diseases using endogenous metabolic modulator (EMM) compositions. They combine biological pathways with developments in systems biology and machine learning. Their proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative, and liver conditions.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $185.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2022)
- Ticker: nasdaq:AXLA
- Website: axcellatx.com
- Phone: +1 617 441 6243
Industries & Categories
Biotechnology, Life Science, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/axcella-148382 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.